Abstract:Objectives: Non-alcoholic steatohepatitis (NASH) is the second most common cause of the hepatitis. In this study, we aimed to investigate the effects and mechanisms of Cyclocarya paliurus (CPF) flavonoids extract in the treatment of NASH. To achieve this, we performed compound target prediction and network analysis based on the method of network pharmacology. We investigated the effect of CPF extract on NASH and the underlying molecular mechanisms using the in vivo pharmacological evaluation technique. Materials and Methods: First, NASH was induced in mice with a high-fat diet. Furthermore, experimental validation was carried out with a high-fat feed-induced NASH mouse model. Chemical compounds and human target proteins of CPF, as well as NASH-related human genes, were obtained from TCMSP, PubChem, and GenBank Database, respectively. Subsequently, molecular networks and typical pathways presumably involved in the treatment of CPF on NASH were performed by Metoscape and String software. Then, the network was constructed by using Cytoscape v3.7.2. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment was performed by using Database for Annotation. Then, the possible underlying mechanisms were studied using the quantitative reverse transcription polymerase chain reaction and Western blot analysis. Results: The network pharmacology research showed that the CPF, which contained 26 compounds and 27 genes, regulated the most signaling pathways related to NASH. Moreover, the protein–protein interaction network based on the targets of CPF on NASH revealed that the core compounds were luteolin, quercetin, kaempferol, ellagic acid, isoquercitrin, gallic acid, inositol, and myricetin, which were regulated by more than 4 compounds, remarkable related with peroxisome proliferator-activated receptor (PPAR) signaling pathway, cholesterol metabolism, bile secretion, type II diabetes mellitus, adenosine 5′-monophosphate-activated protein kinase signaling pathway, and insulin signaling pathway. In addition, carnitine palmitoyltransferase 2, cytochrome P450 family 7 subfamily A member 1 (CYP7A1), cytochrome P450 family 27 subfamily A member 1 (CYP27A1), and fatty acid-binding protein 1 were treated as target genes of CPF in NASH. In vivo experiments indicated that CPF promoted Peroxisome proliferator-activated receptor alpha (PPAR α)/Peroxisome proliferator-activated receptor gamma (PPAR γ) signaling pathway in NASH mouse model. Conclusion: CPF played a role in inhibiting lipid response in NASH, which was closely associated with the modulation effect of CPF on PPAR α/PPAR γ signaling pathway.

Interventional Clinical Trials Using Noninvasive Ultrasound End Points: The Multicenter Isradipine/Diuretic Atherosclerosis Study

Huatan Qushi Formula Alleviates Non-Alcoholic Fatty Liver Disease Via PI3K/Akt Signaling and Gut Microbiota Modulation

Effects of cyclocarya paliurus flavonoid extract in non-alcoholic steatohepatitis mice: Intermeshing network pharmacology and in vivo pharmacological evaluation

Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling

Combined quercetin and simvastatin attenuate hepatic fibrosis in rats by modulating SphK1/NLRP3 pathways

Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis

Amelioration of free fatty acid‐induced fatty liver by quercetin‐3‐O‐β‐D‐glucuronide through modulation of peroxisome proliferator‐activated receptor‐alpha/sterol regulatory element‐binding protein‐1c signaling

(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease.

Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model

[Effects of Soothing Liver and Invigorating Spleen Recipes on NF-kappaB Signal Pathway Related Genes and Proteins in Primary Hepatocytes of Rats with NASH].

Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds

Tetrahydrocurcumin ameliorates hepatic steatosis by restoring hepatocytes lipophagy through mTORC1-TFEB pathway in nonalcoholic steatohepatitis

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis

The combined effect of Raspberry Ketone with Resveratrol against oxidative stress and steatohepatitis in rats: Pharmacokinetic and pharmacodynamic studies

Effect of Combined Prescription of Linggui Zhugan Tang and Yinchenhao Tang on Nrf2/ARE Signaling Pathway in Rats with Non-alcoholic Steatohepatitis

Isoquercitrin attenuates the progression of non-alcoholic steatohepatitis in mice by modulating galectin-3-mediated insulin resistance and lipid metabolism

Combined treatment with pioglitazone and celecoxib for experimental nonalcoholic steatohepatitis

Effect of silibinin on CFLAR-JNK pathway in oleic acid-treated HepG2 cells

Protective effects of syringic acid in nonalcoholic fatty liver in rats through regulation of Nrf2/HO-1 signaling pathway

The alleviating effect of Scutellaria amoena extract on the regulation of gut microbiota and its metabolites in NASH rats by inhibiting the NLRP3/ASC/caspase-1 axis

Isolation of coding sequences from yeast artificial chromosome (Yac). Clones by exon amplification.